MALAT1 and non-small cell lung carcinoma: Thus, IGF2BP2 was demonstrated to enhance MALAT1 stability through m6A modification promoting the protein expression of its downstream target ATG12, thereby facilitating NSCLC progression and reducing patient survival (Table 4).